Nach R0-Resektion führt Pembrolizumab zu beeindruckenden Überlebensraten
- 20 October 2021
- journal article
- Published by Springer Science and Business Media LLC in InFo Hämatologie + Onkologie
- Vol. 24 (10), 31-32
- https://doi.org/10.1007/s15004-021-8816-2
Abstract
No abstract availableThis publication has 3 references indexed in Scilit:
- Comparative efficacy and safety of adjuvant nivolumab versus other treatments in adults with resected melanoma: a systematic literature review and network meta-analysisBMC Cancer, 2021
- Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III MelanomaThe New England Journal of Medicine, 2020
- Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant TherapyThe New England Journal of Medicine, 2016